Clinical Evidence: What STEP Trials Reveal About Swapping
Why Patients Consider Swapping From Mounjaro to Wegovy: Clinical Evidence
The decision to swap from Mounjaro to Wegovy often stems from reviewing published clinical trial data and individual treatment responses. Wegovy's STEP trial programme demonstrated consistent results across multiple studies, with STEP 1 showing approximately 15% average weight loss at 68 weeks when combined with a reduced-calorie diet and increased physical activity (Wilding et al., NEJM, 2021). The SELECT cardiovascular outcomes trial further revealed a 20% reduction in major cardiovascular events, providing additional clinical rationale for treatment selection.
Patients may also consider the practical differences when evaluating whether to swap from Mounjaro to Wegovy, particularly regarding storage requirements and dosing schedules. Both medications require weekly injection, but Wegovy offers superior storage flexibility with 6 weeks room temperature stability once removed from refrigeration, compared to Mounjaro's 21-day limit. This advantage proves particularly valuable for patients who travel frequently or prefer greater medication portability without compromising therapeutic efficacy.
Wegovy Pricing Structure: Transparent Costs for UK Patients
Understanding the financial investment when choosing to swap from Mounjaro to Wegovy requires examining EverydayMeds' comprehensive pricing structure. Single pen prices start at £79.99 for the 0.25mg starter dose (weeks 1-4), progressing to £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the 2.4mg maintenance dose. New customers apply discount code FIRST40 at checkout, whilst returning patients use DOSE25, with these prices representing the final amount paid after discount application.
Our bundle options provide convenient multi-month supply arrangements for patients committed to their weight management journey. The Intro Trio bundle (0.25mg, 0.5mg, and 1mg) costs £299.99, covering the first 12 weeks of treatment, whilst the Ultimate Stability Trio provides three months of maintenance 2.4mg supply for £649.99. These bundles offer supply security and reduced ordering frequency rather than cost savings, ensuring consistent treatment availability throughout your Wegovy programme.
STEP Trial Evidence: What Research Shows About Wegovy Efficacy
Clinical evidence supporting the decision to swap from Mounjaro to Wegovy comes from the robust STEP trial programme involving over 4,500 participants. STEP 1 demonstrated that patients taking Wegovy alongside lifestyle interventions achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo. STEP 3, incorporating intensive behavioural therapy, showed approximately 16% average weight loss, whilst STEP 5 confirmed sustained results of 15.2% at two years.
The SELECT cardiovascular outcomes trial provided additional evidence, demonstrating a 20% reduction in major adverse cardiovascular events in adults with established cardiovascular disease. These findings, published in peer-reviewed journals including the New England Journal of Medicine, provide the clinical foundation for prescribing decisions when patients consider treatment options or transitions between therapies.
How Wegovy Works: GLP-1 Mechanism for Weight Management
Wegovy functions as a GLP-1 receptor agonist, mimicking the action of naturally occurring incretin hormones that regulate blood sugar and appetite. When patients swap from Mounjaro to Wegovy, they transition from a dual GIP/GLP-1 agonist to a selective GLP-1 approach, which may suit individuals who respond well to targeted GLP-1 stimulation. The medication works by slowing gastric emptying, promoting satiety after smaller meals, and reducing food cravings through direct action on brain appetite centres. This mechanism supports weight management when combined with a reduced-calorie diet and increased physical activity. The once-weekly injection schedule provides consistent therapeutic levels, maintaining appetite suppression throughout the week whilst allowing normal daily activities and meal planning.
EverydayMeds Ordering Process: Seamless Treatment Transitions
Patients looking to swap from Mounjaro to Wegovy can complete our streamlined online clinical assessment in approximately three minutes, covering medical history, current medications, and treatment goals. Our qualified prescribers review applications within three working days (or 24 hours with express service), ensuring thorough evaluation of suitability and any necessary transition protocols. Once approved, medications dispatch via next-day delivery using temperature-controlled cold-chain logistics to maintain product integrity. Our GPhC-registered pharmacy (#9012878) operates under full regulatory compliance, providing prescription-only medicines exclusively following appropriate clinical assessment. The entire process from assessment to delivery typically completes within four working days, enabling swift treatment transitions when clinically appropriate.
Storage and Practical Considerations: Wegovy vs Mounjaro Differences
Wegovy requires refrigerated storage at 2-8°C before first use but maintains potency for up to six weeks at room temperature below 30°C once removed from refrigeration. This storage advantage over Mounjaro's 21-day room temperature limit makes Wegovy particularly suitable for frequent travellers or those preferring flexible storage options. The FlexTouch pen design provides intuitive injection with clear dose indicators and safety features. Mandatory dose escalation begins with 0.25mg for four weeks, progressing through 0.5mg, 1mg, and 1.7mg phases before reaching the 2.4mg maintenance dose. This gradual escalation minimises gastrointestinal side effects whilst optimising treatment tolerance and therapeutic response throughout the programme.
UK Clinical Evidence: Real-World Wegovy Results and Patient Outcomes
Beyond clinical trials, UK prescribing data and patient registries provide additional insight for those considering whether to swap from Mounjaro to Wegovy. NICE TA875 recommends Wegovy for adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities, when provided alongside specialist weight management support. The medication carries MHRA additional monitoring status (Black Triangle ▼) as part of comprehensive post-marketing surveillance to monitor real-world safety and efficacy outcomes. UK prescribers report good treatment adherence rates, partly attributed to the once-weekly dosing schedule and superior storage flexibility compared to daily medications.
Patient feedback through regulated healthcare channels indicates particular satisfaction with the gradual dose escalation protocol, which allows natural adjustment to GLP-1 effects whilst maintaining therapeutic progression. The combination of clinical trial evidence and emerging real-world data supports informed decision-making for patients and prescribers evaluating treatment options or considering transitions between different weight management medications available through licensed UK pharmacy channels.
Making the Switch: Expert Support for Treatment Transitions
When patients decide to swap from Mounjaro to Wegovy, our clinical team provides comprehensive support throughout the transition process. Assessment includes reviewing previous treatment response, current health status, and individual circumstances that might influence medication choice or dosing protocols. We coordinate with existing healthcare providers where appropriate, ensuring continuity of care and optimal treatment outcomes. Both Wegovy and Mounjaro remain available through EverydayMeds, allowing prescribers to select the most suitable option based on clinical judgment and patient preference. Complete our online assessment today using discount code FIRST40 for new customers or DOSE25 for returning patients, with express 24-hour prescriber review available for urgent treatment transitions. Visit https://everydaymeds.co.uk/collections/wegovy to begin your assessment and receive expert guidance on your weight management journey.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
